KEY POINTS
- This retrospective dosimetric and computational study evaluated 10 patients with head and neck squamous cell carcinoma, using publicly available planning CT datasets. For each patient, investigators generated conventional intensity-modulated proton therapy (IMPT) and spot-scanning proton arc therapy (PAT) plans in RayStation. High-risk prescriptions ranged from 60 to 74 Gy(RBE), with target and OAR constraints applied using 3-mm setup and 3.5% range uncertainty, including 21 robust optimization scenarios.
- IMPT generally used four static beam angles, while PAT employed one arc with 2.5° angular sampling, corresponding to 144 gantry positions. Circulating blood exposure was estimated using the HEDOS dynamic hematological dose model, simulating 100,000 blood particles at a 0.05-second temporal resolution. Calculations incorporated gantry rotation, beam irradiation time, energy-layer transitions, and physiological blood movement between vascular and tissue compartments, rather than relying on a static whole-body dose distribution.
- Target coverage was maintained with both approaches, with mean nominal CTV V95 of approximately 99.2% for IMPT and PAT. PAT also reduced exposure to several nearby OARs. Mean nominal laryngeal dose decreased from 34.4 to 24.8 Gy(RBE) (p=0.008), left parotid mean dose from 13.5 to 9.6 Gy(RBE) (p=0.004), and spinal cord near-maximum D2% from 14.1 to 5.7 Gy(RBE) (p=0.008). These findings indicate that the blood-dose comparison occurred alongside meaningful differences in overall dose conformity.
- PAT consistently reduced modeled circulating blood dose. Mean blood dose decreased from 0.563 ± 0.212 Gy(RBE) with IMPT to 0.483 ± 0.195 Gy(RBE) with PAT, an approximate 14.2% relative reduction. The dose received by the highest-exposed 90% of simulated blood particles, expressed as D90%, decreased from 0.522 to 0.430 Gy(RBE), while D10% decreased from 0.605 to 0.538 Gy(RBE). All three paired blood-dose comparisons were statistically significant (p=0.002).
- Whole-body integral dose was also lower with PAT, decreasing from a mean modeled value of 0.567 to 0.503 in the study's integral-dose metric (p=0.002). Blood-dose histograms showed consistently lower exposure with arc plans, despite the concern that irradiation from many gantry angles might increase the low-dose bath. PAT also produced a higher mean proportion of simulated blood particles receiving no radiation during a single fraction (0.703% vs 0.015%), although values varied considerably between patients and were close to zero in most cases.
- PAT had a shorter mean simulated irradiation time than IMPT: 391.5 ± 130.3 versus 545.1 ± 86.0 seconds, respectively. To determine whether the difference in blood exposure resulted primarily from treatment duration, the investigators repeated PAT simulations using the same delivery time as IMPT. Mean blood dose changed only minimally, from 0.483 to 0.486 Gy(RBE), suggesting that improved spatial dose distribution, rather than shorter treatment time alone, was the principal contributor. Blood-dose metrics also correlated strongly with target proximity and dose to major blood vessels.
- The investigation was limited to 10 retrospectively planned cases, with no actual PAT treatments, serial lymphocyte counts, or clinical outcomes. HEDOS used reference physiological blood volumes and flow rates rather than patient-specific cardiac output and circulation measurements; delivery was simulated at gantry-angle resolution rather than individual pencil beam spots. Furthermore, circulating blood contains only part of the total lymphocyte population, and the model did not fully characterize irradiation of lymphoid tissues. Thus, the reported dose reduction cannot be directly translated into a proven reduction in radiation-induced lymphopenia.
CLINICAL TAKEAWAY
Proton arc therapy may offer an additional dosimetric advantage over conventional IMPT by reducing modeled radiation exposure to circulating blood while maintaining target coverage and improving several OAR metrics. The findings challenge concerns that broader angular irradiation necessarily increases hematological dose, but prospective lymphocyte measurements and clinical validation are required before attributing immune preservation or survival benefits to this technique.